Osanetant

DB04872InvestigationalSmall molecule

Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a... In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.

Mechanism: The mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.
Curator reviewed
Primary indication: Potential therapy for schizophrenia, depression and visceral pain.Curator reviewed
Formula / weight: C₃₅H₄₁Cl₂N₃O₂ · 606.625 g/mol (avg)
Code names: SR-142801

Resolves to

Compound

UNIIK7G81N94DTCAS160492-56-8ChEMBLCHEMBL346178ChEBI748617PubChem219077

Structure

InChIKeyDZOJBGLFWINFBF-UMSFTDKQSA-NSMILESCN(C(C)=O)C1(CCN(CCC[C@@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1

Targets

P29371TACR3

What you can answer from here — as of October 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

718Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Osanetant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account